Skip to main content
JW PHARMACEUTICAL logo

JW PHARMACEUTICAL — Investor Relations & Filings

Ticker · 001060 ISIN · KR7001060003 KO Manufacturing
Open in API
Filings indexed 310 across all filing types
Latest filing 2023-02-08 Governance Information
Country KR South Korea
Listing KO 001060

About JW PHARMACEUTICAL

https://www.jw-pharma.co.kr/pharma/en/m…

JW Pharmaceutical is a company focused on the research, development, and commercialization of pharmaceutical products. It provides a broad portfolio of therapeutic drugs, including specialty medicines and over-the-counter (OTC) solutions. Key product areas include nutritional infusions (Combiflex®, Winuf®), treatments for neutropenia (Neutrogin®), and cardiovascular medicines (Livalo®). Its consumer healthcare offerings feature the Hi-mom® brand of advanced wound care products. The company emphasizes innovation, advancing a pipeline of new drugs targeting oncology and immune diseases. This research is driven by proprietary technology platforms and includes candidates such as the gout treatment Epaminurad.

Recent filings

Filing Released Lang Actions
공정거래자율준수프로그램운영현황(안내공시)
Governance Information Classification · 100% confidence The document is a regulatory filing from JW Pharmaceutical regarding their 'Compliance Program' (CP) status, detailing past performance and future operational plans. This type of disclosure is a standard regulatory announcement in the Korean market (KIND system) for companies to report on their internal governance and compliance activities. Since it does not fit into specific financial reporting categories like 10-K or IR, and it is a direct disclosure of operational status rather than a mere announcement of a report's availability, it is best classified as a Regulatory Filing (RNS).
2023-02-08 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) from JW Pharmaceutical. It details specific changes in share ownership by individuals associated with the company (e.g., Lee Ki-hwan). While it involves shareholding changes, it is specifically a notification of changes in significant share ownership levels by major shareholders/insiders, which aligns with the 'Major Shareholding Notification' category.
2022-12-23 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed in South Korea, which is a regulatory requirement under the Capital Markets Act when a shareholder's stake crosses certain thresholds (typically 5%). This document details the shareholding changes of JW Holdings and its special related parties in JW Shinyak. It is a standard regulatory filing for major shareholding notifications.
2022-12-23 Korean
기타안내사항(안내공시)
Share Issue/Capital Change Classification · 100% confidence The document is a short regulatory announcement from JW Pharmaceutical regarding the expiration of the mandatory holding period for specific preferred shares (2우선주). It provides details on the number of shares, the holder, and the expiration date. Since it does not fit into specific categories like share issuance or director dealings, and serves as a general regulatory notice regarding corporate share status, it is classified as a Regulatory Filing (RNS).
2022-12-21 Korean
투자판단관련주요경영사항
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from JW Pharmaceutical regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the submission of an Investigational New Drug (IND) application for a Phase 3 clinical trial of their gout treatment, epaminurad, to the Taiwan Food and Drug Administration (TFDA). This type of disclosure is a standard regulatory announcement for material corporate events in the Korean market (KRX). Since it does not fit into specific categories like M&A, dividends, or financial reports, it is classified as a general Regulatory Filing (RNS).
2022-12-19 Korean
수시공시의무관련사항(공정공시)
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from JW Pharmaceutical regarding the planned cash dividend for the 2022 fiscal year. It specifies the dividend amount per share type and the record date. Since it is an official announcement of dividend amounts and payment details for shareholders, it falls under the 'Notice of Dividend Amount' category.
2022-12-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.